Hepatitis B vaccination schedules in genitourinary medicine clinics.
OBJECTIVE
To compare two vaccination schedules in delivering hepatitis B vaccine to at-risk genitourinary medicine clinic attenders.


METHODS
Genitourinary medicine clinic of St Thomas' Hospital, London, UK.


METHODS
Two vaccination protocols were compared. Between January 1991 and December 1992, individuals had doses of recombinant hepatitis B vaccine at 0, 1 and 6 months (standard). From January until October 1993 doses of vaccine were administered at 0, 1 and 2 months (accelerated), following which timing of a booster dose was made on the basis of hepatitis B surface antibody (anti-HBs) assessment. Case notes were reviewed with regard to compliance rates and anti-HBs levels.


RESULTS
Two hundred and fourteen individuals were included (standard 104, accelerated 110). Of the standard group 80.8% and 61.5% attended for the 2nd and 3rd doses respectively compared with 80.0% and 75.5% of the accelerated group (attendance for the 3rd dose chi 2 = 4.19, p < 0.05). For both of these groups compliance was significantly better in those who requested vaccination rather than being offered it opportunistically (chi 2 = 4.86, p < 0.05). Seroconversion rates were not significantly different between the two groups (87.5% versus 83.1%). A significantly higher proportion of the standard group, however, achieved anti-HBs levels greater than 100 i.u./l.


CONCLUSIONS
Completion of hepatitis B vaccination was improved by changing to a 0, 1 and 2 month protocol. Levels of anti-HBs achieved in the accelerated group, however, were lower. If it is confirmed that maintaining anti-HBs levels is not important in retaining protection against hepatitis B then the accelerated schedule has clear advantage. If not, the advantages may be nullified by the need, in some, for an early booster.
Asboe
D
D
Department of Genitourinary Medicine, St Thomas' Hospital, Lambeth, London.
Rice
P
P
de Ruiter
A
A
Bingham
J S
JS
D000293:Adolescent; D000328:Adult; D002985:Clinical Protocols; D005260:Female; D052776:Female Urogenital Diseases / Q000517:prevention & control*; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D052801:Male Urogenital Diseases; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D010349:Patient Compliance; D012189:Retrospective Studies
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines